Hansoh Pharmaceutical Group Company Limited (HKG: 3692)

Market Cap	100.77B
Revenue (ttm)	13.00B
Net Income (ttm)	5.07B
Shares Out	5.93B
EPS (ttm)	0.81
PE Ratio	20.85
Forward PE	23.33
Dividend	0.40 (2.39%)
Ex-Dividend Date	Sep 20, 2024

Volume	4,879,793
Average Volume	4,650,766
Open	16.70
Previous Close	16.84
Day's Range	16.70 - 17.28
52-Week Range	11.18 - 22.80
Beta	0.65
RSI	48.88
Earnings Date	Mar 27, 2025

About Hansoh Pharmaceutical Group Company

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameini...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 9,123
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3692

Financial Performance

In 2023, Hansoh Pharmaceutical Group Company's revenue was 10.10 billion, an increase of 7.69% compared to the previous year's 9.38 billion. Earnings were 3.28 billion, an increase of 26.85%.

Financial numbers in CNY